C-Path inaugural Global Impact Conference: Pioneering drug development collaborations

Sept. 9-11, 2024, Washington, D.C.

2024-08-08

(Press-News.org) TUCSON, Ariz., August 7, 2024 – Critical Path Institute (C-Path), whose mission is to lead collaborations that accelerate drug development, advancing better treatments for people worldwide, is proud to announce its inaugural C-Path Global Impact Conference (CGIC), taking place from September 9-11, 2024, at the Washington Marriott at Metro Center.

The conference represents a significant expansion of C-Path’s mission, focusing on critical areas of drug development. These areas highlight how C-Path’s areas of core excellence — data management and standards, biomarkers, modeling and analytics, regulatory science, and clinical outcome assessments — interlink across all stages of drug development, demonstrating the value of C-Path’s public-private partnership model. By bringing together industry leaders, regulatory agencies, academic researchers, and patient advocates, the conference will incubate productive dialogues addressing the challenges and opportunities within drug development.

C-Path is also excited to confirm the participation of key leaders from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) throughout the three-day conference. Leading figures from both regulatory bodies will serve as in-person panelists, contributing their expertise to diverse discussions. Their active roles offer attendees a unique opportunity to gain firsthand knowledge and actionable guidance from regulatory experts at the forefront of drug development.

Klaus Romero, M.D., M.S., FCP, CEO of C-Path, expressed his enthusiasm for the first-of-its-kind conference, stating, “CGIC serves as a crucial forum for stakeholders from across the drug development landscape to share insights, strategies, and innovations. Our goal is to drive discussions that will lead to actionable solutions for accelerating the availability of therapies for individuals and families worldwide. Put simply, CGIC is the conference that drug developers cannot afford to miss.”

The event will feature a series of presentations and panel discussions designed to spark innovation and promote the sharing— and alignment — of best practices and solutions to accelerate drug development. Attendees will have the opportunity to engage in in-depth discussions on integrating insights across therapeutic areas, navigating regulatory landscapes, and harnessing novel technologies in drug development.

The conference will also highlight the power of public-private partnerships in advancing drug development and regulatory science, demonstrating how collaborative approaches can lead to breakthroughs in treatment discovery and development.

Registration for the CGIC is now open. For more information about the conference and to register, please visit: https://web.cvent.com/event/e25a101c-7408-4295-b318-4073790c6f27/summary.

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path in Europe is headquartered in Amsterdam, Netherlands with additional staff in multiple other locations. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250, and 45% funded by non-government source(s), totaling $14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

Media Contacts:

Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org

Kissy Black
C-Path
615.310.1894
kblack@c-path.org

END

ELSE PRESS RELEASES FROM THIS DATE:

Skin-to-skin ‘kangaroo care’ found to boost neurodevelopment in preemies

2024-08-08

Skin-to-skin cuddling with a parent has lasting cognitive benefits for premature babies, according to a new Stanford Medicine study. Preemies who received more skin-to-skin contact, also known as kangaroo care, while hospitalized as newborns were less likely to be developmentally delayed at 1 year of age, the study found. The research, which was published online July 11 in the Journal of Pediatrics, showed that even small increases in the amount of skin-to-skin time made a measurable difference in the babies’ neurologic development during their first year. “It’s ...

Scientists lay out revolutionary method to warm Mars

2024-08-08

Ever since we learned that the surface of planet Mars is cold and dead, people have wondered if there is a way to make it friendlier to life. In a groundbreaking study published Aug. 7 in Science Advances, researchers from the University of Chicago, Northwestern University, and the University of Central Florida have proposed a revolutionary approach towards terraforming Mars. This new method, using engineered dust particles released to the atmosphere, could potentially warm the Red Planet by more ...

Sugar-sweetened beverage intake increasing globally among children and teens

2024-08-08

A new global analysis of the dietary habits of children and adolescents from 185 countries revealed that youth, on average, consumed nearly 23% more sugar-sweetened beverages in 2018 compared to 1990. Overall, intakes were similar in boys and girls, but higher in teens, urban residents, and children of parents with lower levels of education. Researchers from the Friedman School of Nutrition Science and Policy at Tufts University published the findings Aug. 7 in The BMJ. The study drew from the Global Dietary Database, a large comprehensive compilation of what people around the world eat or drink, to generate the first global estimates and trends of sugar-sweetened ...

Sugary drink intake by children and adolescents increased by almost a quarter between 1990 and 2018

2024-08-08

Children and adolescents across the world consumed on average 23% more sugar sweetened beverages (SSBs) in 2018 than they did in 1990, show the results of a study published in The BMJ today. Over the same period, a corresponding rise was seen in the prevalence of obesity among young people. Unhealthy diets, especially intake of sugar sweetened beverages, play a crucial role in obesity. Although tracking the consumption of these drinks by children and adolescents is essential to understanding ...

New evidence casts doubt on a much-hyped blood test for early cancer detection

2024-08-08

New evidence published by The BMJ today casts doubt on a much-hyped blood test for the NHS that promises to detect more than 50 types of cancer. The test, called Galleri, has been hailed as a “ground-breaking and potentially life-saving advance” by its maker, the California biotech company Grail, and the NHS is currently running a £150m Grail-funded trial of the test involving more than 100,000 people in England, report Dr Margaret McCartney and investigative journalist Deborah Cohen. NHS England claims the test can identify many cancers that “are difficult to ...

Radiotherapy benefits last a decade, breast cancer study reveals

2024-08-08

Providing radiotherapy after surgery could prevent breast cancer from returning in the same place for up to 10 years, a long-term study suggests. This protective effect is limited after a decade, when the risk of cancer recurrence is similar to that in those who have not received radiotherapy. The findings provide a more complete picture of the long-term benefits of radiotherapy following breast cancer surgery, experts say. Surgery followed by radiotherapy remains the standard care for women with ...

Prescription painkiller misuse and addiction are widespread in chronic pain patients

2024-08-08

A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder. This review provides a more accurate -- and more concerning -- rate of opioid misuse than has previously been calculated. It was conducted by researchers at the University of Bristol, funded by the National Institute for ...

When mammoths roamed Vancouver Island: SFU and Royal BC Museum delve into beasts’ history in our region

2024-08-07

Mammoths, the massive pre-historic ice age cousins of the modern-day elephant, have always been understood to have inhabited parts of British Columbia, but the question of when has always been a bit woolly. Now, a new study from Simon Fraser University has given scientists the clearest picture yet when the giant mammals roamed Vancouver Island. As part of SFU researcher Laura Termes’ PhD and published earlier this month in the Canadian Journal of Earth Sciences, the study examined 32 suspected mammoth samples collected on Vancouver Island. Of those samples, just 16 ...

Ochsner Health welcomes Mary Claire Curet, MD, as first Ochsner Physician Scholar

2024-08-07

Lafayette, La. – Ochsner Health is excited to announce that Mary Claire Curet, MD, is joining the team at St. Martinville Family Medicine, an Ochsner primary care practice. Dr. Curet, a native of New Iberia, is the first Ochsner Physician Scholar and brings a wealth of knowledge and a deep commitment to her community. “We are thrilled to welcome Dr. Curet to the Ochsner family,” said Leonardo Seoane, MD, Founding Dean of Xavier Ochsner College of Medicine and Executive Vice President and Chief Academic Officer for Ochsner Health. “Her dedication and passion for primary care, particularly in underserved ...

Discovering how plants make life-and-death decisions

2024-08-07

Researchers at Michigan State University have discovered two proteins that work together to determine the fate of cells in plants facing certain stresses. Ironically, a key discovery in this finding, published recently in Nature Communications, was made right as the project's leader was getting ready to destress. Postdoctoral researcher Noelia Pastor-Cantizano was riding a bus to the airport to fly out for vacation, when she decided to share a promising result she had helped gather a day earlier. “I didn’t want to wait ten days until I came back to send it. It took almost two years to get there,” said Pastor-Cantizano, who then worked ...

LAST 30 PRESS RELEASES:

Study shows psychedelic drug psilocybin gives comparable long-term antidepressant effects to standard antidepressants, but may offer additional benefits

Study finds symptoms of depression during pregnancy linked to specific brain activity: scientists hope to develop test for “baby blues” risk

UK study shows there is less stigma against LGBTQ people than you might think, but people with mental health problems continue to experience higher levels of stigma